Last week, the Patent Trial and Appeal Board (“Board”) instituted inter partes review of two patents directed to methods of administering adalimumab for the treatment of psoriasis, based on petitions filed by Sandoz: IPR2017-02105 (challenging U.S. Pat. No. 9,090,689) and IPR2017-02106 (challenging U.S. Pat. No. 9,067,992).
Separately, the Board issued IPR institution decisions on U.S. Pat. No. 7,976,838, which is directed to methods of treating rheumatoid arthritis with an antibody that binds CD20, including rituximab. The Board denied institution in IPR2017-02042 and IPR2017-02036, both filed by Sandoz. However, the same panel instituted inter partes review of the ’838 patent in IPR2017-01923, filed by Pfizer.
Stay tuned to Big Molecule Watch for more biologics IPR updates.
The post IPR Updates Relating to Adalimumab and Rituximab appeared first on Big Molecule Watch.